Nitric oxide, the kidney, and hypertension

American Journal of Hypertension

Volumn 10, Issue 1, 1997, Pages 129-140

  Lahera, Vicente ^a   Navarro Cid, Josefa ^a   Cachofeiro, Victoria ^a   García Estañ, Joaquin ^b   Ruilope, Luis M ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

angiotensin converting enzyme inhibitors; arterial hypertension; L arginine; natriuresis; nitric oxide; nitric oxide deficiency; proteinuria

Indexed keywords

8 BROMO CYCLIC AMP; ARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

HEMODYNAMICS; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; NATRIURESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; VASCULAR RESISTANCE;

ANIMALS; HUMANS; HYPERTENSION; KIDNEY; NITRIC OXIDE;

EID: 0031016116     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00346-9     Document Type: Review

References (101)

1. Guyton AC, Coleman TG, Cowley AW Jr, et al. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation in hypertension. Am J Med. 52:1972;584-594.
2. Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res. 36:1975;692-696.
3. Bianchi G, Fox U, DiFrancesco GF, et al. The hypertensive role of the kidney in spontaneously hypertensive rats. Clin Sci. 45:1973;135S-139S.
4. Rettig R, Folberth C, Stauss H, et al. Role of the kidney in primary hypertension. A renal transplantation study in rats. Am J Physiol. 258:1990;F606-F611.
5. de Wardener HE. The primary role of the kidney and salt intake in the aetiology of essential hypertension: part I. Clin Sci. 79:1990;193-200.
6. Uyehara CFT, Gellai M. Impairment of renal function precedes establishment of hypertension in spontaneously hypertensive rats. Am J Physiol. 34:1993;R943-R950.
7. Brod J, Bahlman J, Cachovan M, Pretschner PD. Development of hypertension in renal disease. Clin Sci. 64:1983;141-152.
8. Curtis JJ, Luke RG, Dustan HP, et al. Remission of essential hypertension after renal transplantation. N Eng J Med. 309:1983;1009-1015.
9. Elliott P. Observational studies of salt and blood pressure. Hypertension. 17:((suppl I)):1991;I3-I8.
10. Stamler J, Rose G, Elliott P, et al. Findings of the International Cooperative Intersalt Study. Hypertension. 17:((suppl I)):1991;I9-I15.
11. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I. Analysis of observational data among populations. Br Med J. 302:1991;811-815.
12. Aviv A, Lasker N. Proposed defects in membrane transport and intracellular ions as pathogenic factors in essential hypertension. Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis and Management. 1990;923-937 Raven Press, New York.
13. Weder AB. Membrane sodium transport and salt sensitivity of blood pressure. Hypertension. 17:((suppl I)):1991;I74-I80.
14. Brenner BM, Garcia D, Anderson S. Glomeruli and blood pressure: less of one, more the other? 1:1988;335-347.
15. Sealey JE, Blumenfeld JD, Bell GM, et al. On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens. 6:1988;763-777.
16. Ruilope LM, Lahera V, Rodicio JL, et al. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension? Hypertension. 23:1994;3-9.
17. Romero JC, Knox FG. Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. Hypertension. 11:1988;724-738.
18. Roman RJ, Zou AP. Influence of the renal medullary circulation on the control of sodium excretion. Am J Physiol. 34:1993;R963-R973.
19. Hall JE. Renal function in one-kidney, one-clip hypertension and low renin essential hypertension. 4:1991;523S-533S.
20. Goldblatt H, Lynch J, Hanzal RF, et al. Studies on experimental hypertension. 1: The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 59:1934;347-379.
21. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 62:1982;347-504.
22. Folkow B. Kidneys and primary hypertension: initatiors, stabilizers or/and victim-aggravators? Blood Pressure. 3:1994;212-215.
23. Göthberg G, Folkow B. Age-dependent alterations in the structurally determined vascular resistance, pre- to postglomerular resistance ratio and glomerular filtration capacity in kidneys, as studied in aging normotensive rats and spontaneously hypertensive rats. Acta Physiol Scand. 117:1983;547-555.
24. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
25. Furchgott RF. Role of endothelium in responses to vascular smooth muscle. Cir Res. 53:1983;557-573.
26. De Mey JG, Claeys M, Vanhoutte PM. Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther. 222:1982;166-173.
27. De Mey JG, Vanhoutte PM. Role of the intima in cholinergic and prurinergic relaxation of isolated canine femoral arteries. J Physiol. 335:1983;65-74.
28. Van de Voorde J, Leusen I. Role of endothelium in the vasodilator response of rat thoracic aorta to histamine. Eur J Pharmacol. 87:1983;113-120.
29. Lüscher TF, Cooke JP, Houston DS, et al. Endothelium-dependent relaxations in human arteries. Mayo Clin Proc. 62:1987;601-606.
30. Thom S, Hughes A, Martin G, et al. Endothelium-dependent relaxation in isolated human arteries and veins. Clin Sci. 73:1987;547-552.
31. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:1989;997-1000.
32. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 315:1986;1046-1051.
33. Forsterman U, Mugge A, Alheid U, et al. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res. 62:1988;185-190.
34. Panza JA, Quyyumi AA, Brush JE Jr, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 323:1990;22-27.
35. Linder L, Kiowski W, Buhler FR, et al. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation. 81:1990;1762-1767.
36. Ribeiro MO, Antunes E, de Nucci G, et al. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension. 20:1992;298-303.
37. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Ciln Invest. 90:1992;278-281.
38. Jover B, Herizi A, Ventre F, et al. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension. 21:1993;944-948.
39. Navarro J, Sanchez A, Saiz J, et al. Hormonal, renal and metabolic alterations during the hypertension induced by chronic inhibition of nitric oxide in rats. Am J Physiol. 267:1994;R1516-R1521.
40. Gardiner SM, Kemp PA, Bennett T, et al. Nitric oxide synthesis inhibitors cause sustained, but reversible, hypertension and hindquarters vasoconstriction in Brattleboro rats. Eur J Pharmacol. 213:1992;449-451.
41. Wang YX, Gavras I, Wierzba, et al. Inhibition of nitric oxide, bradykinin, and prostaglandins in normal rats. Hypertension. 19:((suppl II)):1992;II-255-II-261.
42. Chen PY, Sanders PW. L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 88:1991;1559-1567.
43. Chen PY, Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension. 22:1993;812-818.
44. Ruilope LM, Lahera V, Rodicio JL, et al. Participation of nitric oxide in the regulation of renal function: possible role in the genesis of arterial hypertension. J Hypertens. 12:1994;625-631.
45. Ito S. Nitric oxide in the kidney: Current opinion in nephrology and hypertension. 4:1995;23-30.
46. G-nitro-L-arginine methylester on renal function and blood pressure. Am J Physiol. 261:1991;F1033-F1037.
47. Lahera V, Navarro J, Biondi ML, et al. Exogenous cGMP prevents decrease in diuresis and natriuresis induced by inhibition of NO synthesis. Am J Physiol. 264:1993;F344-F347.
48. Salom MG, Lahera V, Guardiola F, et al. Blockade of pressure natriuresis induced by inhibition of renal synthesis of nitric oxide in dogs. Am J Physiol. 262:1992;F718-F722.
49. Biondi ML, Dousa TP, Vanhoutte PM, et al. Evidences for the existence of endothelium-derived relaxing factor in the renal medulla. Am J Hypertension. 3:1990;876-878.
50. Mattson DL, Roman RJ, Cowley AW. Role of nitric oxide in renal papillary blood flow and sodium excretion. Hypertension. 19:1992;766-769.
51. Mattson DL, Higgins DJ. Influence of dietary sodium intake on renal medullary nitric oxide synthase. Hypertension. 27:((part 2)):1996;688-692.
52. Atucha NM, Ramirez A, Quesada T, et al. Effects of nitric oxide inhibition on the renal papillary blood flow response to saline-induced volume expansion in the rat. Clin Sci. 86:1994;405-409.
53. G-monomethyl-L-arginine. Circ Res. 75:1994;829-835.
54. Fenoy FJ, Ferrer P, Carbonell LF, et al. Role of nitric oxide on papillary blood flow and pressure natriuresis. Hypertension. 25:1995;408-414.
55. Ortiz MC, Atucha NM, Lahera V, et al. Importance of nitric oxide and prostaglandins in the control of the rat renal papillary circulation. Hypertension. 27:1996;377-381.
56. Salazar FJ, Alberola A, Pinilla JM, et al. Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition. Hypertension. 22:1993;49-55.
57. Alberola A, Pinilla JM, Quesada T, et al. Role of nitric oxide in mediating renal response to volume expansion. Hypertension. 19:((suppl 6)):1992;780-784.
58. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat. J Clin Invest. 91:1993;642-650.
59. G-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br J Pharmacol. 101:1990;10-12.
60. Hu L, Manning D Jr, Brands MW. Long-term cardiovascular role of nitric oxide in conscious rats. Hypertension. 23:1994;185-194.
61. García-Estañ J, Navarro J, Atucha NM, et al. Chronic effects of nitric oxide and prostaglandin inhibition on pressure diuresis and natriuresis in rats. Kidney Int. 49:((suppl 55)):1996;S141-S143.
62. Nakanishi K, Mattson DL, Cowley AW. Role of renal medullary blood flow in the development of L-NAME hypertension in rats. Am J Physiol. 268:1995;R317-R323.
63. Mattson DL, Lu S, Papanek PE, Cowley AW. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol. 266:1994;H1918-H1926.
64. Haack D, Mohring J, Mohring B, et al. Comparative study on development of corticosterone and DOCA hypertension in rats. Am J Physiol. 233:1977;F403-F411.
65. Vidal MJ, Romero JC, Vanhoutte PM. Endothelium-derived relaxing factor inhibits renin release. Eur J Pharmacol. 149:1988;401-402.
66. Sigmon DH, Carretero OA, Beierwaltes WH. Endothelium-derived relaxing factor regulates renin release in vivo. Am J Physiol. 263:1992;F256-F261.
67. Persson PB, Baumenn JE, Ehmke H, et al. Endothelium-derived NO stimulates pressure-dependent renin release in conscious dogs. Am J Physiol. 264:1993;F943-F947.
68. Zanchi A, Schaad CN, Osterheld MC, et al. Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol. 268:1995;H2267-H2273.
69. Tojo A, Gross SS, Zhang L, et al. Immunocytochemical localization of distinct isoforms of nitric oxide synthase in the juxtaglomerular apparatus of normal rat kidney. J Am Soc Nephrol. 4:1994;1438-1447.
70. Ito S, Johnson CS, Carretero OA. Modulation of angiotensin II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest. 87:1991;1656-1663.
71. De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II: glomerular and tubular interaction in the rat. J Clin Invest. 89:1992;1248-1256.
72. Sigmon DH, Carretero OA, Beierwaltes WH. Angiotensin-dependence of endothelium-mediated renal hemodynamics. Hypertension. 20:1992;643-650.
73. Pollock DM, Polakowski JS, Divish BJ, et al. Angiotensin blockade reverses hypertension during long term nitric oxide synthetase inhibition. Hypertension. 21:1993;660-666.
74. Qiu C, Engels K, Baylis C. Importance of angiotensin II and α -adrenergic tone in chronic nitric oxide in rats. Am J Physiol. 23:1994;971-975.
75. Qui C, Engels K, Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol. 6:1995;1476-1481.
76. Navarro-Cid J, Maeso R, Rodrigo E, et al. Renal and vascular consequences of the chronic nitric oxide synthase inhibition: effects of antihypertensive drugs. Am J Hypertens. 9:1996;1077-1083.
77. Fujihara CK, Michellazo SM, de Nucci G, et al. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol. 266:1994;F697-F705.
78. Okamura M, Konishi Y, Nishimura M, et al. Ehancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects on TCV-116, a novel angiotensin II receptor antagonist. Blood Pressure. 3:((suppl 5)):1994;75-78.
79. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses LNAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension. 27:1996;176-183.
80. Vriesendorp R, Donker AJM, de Zeeuw D, et al. Antiproteinuric effect of naproxen and indomethacin. Am J Nephrol. 5:1985;236-242.
81. 2 excretion in the nephrotic syndrome by nonsteroidal anti-inflammatory drugs. Clin Nephrol. 25:1986;105-110.
82. Craven PA, Melhem MF, DeRubertis FR. Thromboxane in pathogenesis of glomerular injury in diabetes. Kidney Int. 42:((4)):1992;934-943.
83. Bouriquet N, Dupont M, Herizi A, et al. Preglomerular sudanophilia in LNAME hypertensive rats. Involvement of endothelin. Hypertension. 27:((part 1)):1996;382-391.
84. Morton JJ, Beattie EC, Speirs A, et al. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens. 11:1993;1083-1088.
85. Li Jin-Sheng, Schiffrin EL. Resistance artery structure and neuroeffector mechanisms in hypertension induced by nitric oxide synthase. 7:1994;996-1004.
86. Delacretaz E, Hayoz D, Osterheld MC, et al. Long-term nitric oxide synthase inhibition and distensibility of carotid artery in intact rats. Hypertension. 23:1994;967-970.
87. Ikenaga H, Suzuki H, Ishii N, et al. Role of NO on pressure-natriuresis in Wistar-Kyoto and spontaneously hypertensive rats. Kidney Int. 43:1993;205-211.
88. Larson TS, Lockhart JC. Restoration of vasa recta hemodynamics and pressure natriuresis in SHR by L-arginine. Am J Physiol. 268:1995;F907-F912.
89. Patel A, Layne S, Watts D, Kirchner KA. L-Arginine administration normalizes pressure natriuresis in hypertensive Dahl rats. Hypertension. 22:1993;863-869.
90. Hu L, Manning RD. Role of nitric oxide in regulation of long-term pressure-natriuresis relationship in Dahl rats. Am J Physiol. 268:1995;H2375-H2383.
91. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 10:1992;1025-1031.
92. Panza JA, Casino PR, Kilcoyne RN, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 87:1993;1468-1474.
93. Panza JA, Casino PR, Badar DM, et al. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 87:1993;1475-1481.
94. Panza JA, Casino PR, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol. 23:1994;1610-1616.
95. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human essential hypertension. Hypertension. 21:1993;929-933.
96. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 21:1993;1145-1151.
97. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension. 25:1995;699-703.
98. Higashi Y, Oshima T, Ozono R, et al. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension. 25:((part 2)):1995;898-902.
99. Mimran A, Ribstem J, Ducailar G. Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension. 26:((part 1)):1995;937-941.
100. Campo C, Lahera V, García-Robles R, et al. Aging abolishes the renal response to L-arginine in essential hypertension. Kidney Int. 49:((suppl 55)):1996;S126-S128.
101. Gerhard M, Roddy MA, Creager SJ, et al. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of human. Hypertension. 27:1996;849-853.